JETREA

This brand name is authorized in Austria, Australia, Cyprus, Estonia, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, United Kingdom, United States

Active ingredients

The drug JETREA contains one active pharmaceutical ingredient (API):

1 Ocriplasmin UNII 7V6HE3DM5A - OCRIPLASMIN

Ocriplasmin has a proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen) and aims to dissolve the protein matrix responsible for the abnormal vitreomacular adhesion (VMA). Read about Ocriplasmin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JETREA Concentrate for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01XA22		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11798Y
Country: EE	Ravimiamet	Identifier(s): 1610075, 1684122
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 360251
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7598
Country: IT	Agenzia del Farmaco	Identifier(s): 042736013, 042736025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069744, 1076836
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 106062
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100297103, 100344104
Country: US	FDA, National Drug Code	Identifier(s): 24856-002